CA3302760A1 - Btla-binding (cd272) antibodies for modulating immune response and treating disease - Google Patents

Btla-binding (cd272) antibodies for modulating immune response and treating disease

Info

Publication number
CA3302760A1
CA3302760A1 CA3302760A CA3302760A CA3302760A1 CA 3302760 A1 CA3302760 A1 CA 3302760A1 CA 3302760 A CA3302760 A CA 3302760A CA 3302760 A CA3302760 A CA 3302760A CA 3302760 A1 CA3302760 A1 CA 3302760A1
Authority
CA
Canada
Prior art keywords
seq
pat
amino acid
variable region
chain variable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3302760A
Other languages
English (en)
Inventor
Brian A. Zabel
John A. Lippincott
Yayue Zheng
Megha Vaman Rao
Miao Tan
David P. MEININGER
Original Assignee
Trianni Inc
Curia IP Holdings LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trianni Inc, Curia IP Holdings LLC filed Critical Trianni Inc
Publication of CA3302760A1 publication Critical patent/CA3302760A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Psychiatry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3302760A 2019-04-01 2020-03-31 Btla-binding (cd272) antibodies for modulating immune response and treating disease Pending CA3302760A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962827744P 2019-04-01 2019-04-01
US62/827,744 2019-04-01
CA3135836A CA3135836A1 (en) 2019-04-01 2020-03-31 Btla-binding (cd272) antibodies for modulating immune response and treating disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA3135836A Division CA3135836A1 (en) 2019-04-01 2020-03-31 Btla-binding (cd272) antibodies for modulating immune response and treating disease

Publications (1)

Publication Number Publication Date
CA3302760A1 true CA3302760A1 (en) 2026-05-13

Family

ID=70296156

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3302760A Pending CA3302760A1 (en) 2019-04-01 2020-03-31 Btla-binding (cd272) antibodies for modulating immune response and treating disease
CA3135836A Pending CA3135836A1 (en) 2019-04-01 2020-03-31 Btla-binding (cd272) antibodies for modulating immune response and treating disease

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3135836A Pending CA3135836A1 (en) 2019-04-01 2020-03-31 Btla-binding (cd272) antibodies for modulating immune response and treating disease

Country Status (8)

Country Link
US (2) US11384146B2 (enExample)
EP (1) EP3946622A1 (enExample)
JP (3) JP7596298B2 (enExample)
KR (1) KR20220047536A (enExample)
CN (2) CN114585416B (enExample)
CA (2) CA3302760A1 (enExample)
IL (1) IL286838A (enExample)
WO (1) WO2020205849A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023004633A (es) * 2020-10-23 2023-05-12 Anaptysbio Inc Moduladores del atenuador de linfocitos b y t (btla) y metodo de uso de los mismos.
MX2024007054A (es) * 2021-12-10 2024-09-04 Merck Sharp & Dohme Llc Aglutinantes de mesotelina humana.
EP4469558A4 (en) * 2022-01-29 2026-02-25 Hifibio Inc Anti-BTLA antibodies and their uses in cancer treatment
AU2023212896A1 (en) * 2022-01-29 2024-08-22 Hifibio, Inc. Antibody against btla and uses thereof
US20230322929A1 (en) * 2022-04-12 2023-10-12 Shanghai Junshi Biosciences Co., Ltd. Compositions and Methods for Treating Solid Tumors with Anti-BTLA as Mono or Combination Therapy
EP4558226A1 (en) * 2022-07-19 2025-05-28 Staidson Biopharma Inc. Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2025250861A1 (en) * 2024-05-31 2025-12-04 Icahn School Of Medicine At Mount Sinai Broadly neutralizing anti-hcmv antibodies and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US7153950B2 (en) 2002-10-25 2006-12-26 Genentech, Inc. Nucleic acids encoding an immune related polypeptide
JP2007512846A (ja) 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
AR066170A1 (es) * 2007-09-26 2009-07-29 Genentech Inc Anti integrina alfa 5 beta 1
CA2769473A1 (en) 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
CA2961439A1 (en) 2014-11-05 2016-05-12 Genentech, Inc. Anti-fgfr2/3 antibodies and methods using same
EP3288587A4 (en) 2015-04-29 2018-09-12 Sanford-Burnham Medical Research Institute Modulation of immune response using btla agonist antibodies
JP7227007B2 (ja) 2015-12-02 2023-02-21 ストサイエンシス， インコーポレイテッド グリコシル化ｂｔｌａ（ｂ－及びｔ－リンパ球減弱因子）に特異的な抗体
CA3013333A1 (en) * 2016-02-26 2017-08-31 Inserm (Institut National De La Sante Et De La Recherche Medicale) Antibodies having specificity for btla and uses thereof
PE20190115A1 (es) * 2016-04-15 2019-01-16 Immunext Inc Anticuerpos vista antihumanos y su uso

Also Published As

Publication number Publication date
US20230340123A1 (en) 2023-10-26
JP2022528005A (ja) 2022-06-07
CA3135836A1 (en) 2020-10-08
JP2026102772A (ja) 2026-06-23
JP7596298B2 (ja) 2024-12-09
WO2020205849A1 (en) 2020-10-08
EP3946622A1 (en) 2022-02-09
CN114585416B (zh) 2025-01-17
US20200325230A1 (en) 2020-10-15
IL286838A (en) 2021-10-31
CN119735682A (zh) 2025-04-01
CN114585416A (zh) 2022-06-03
KR20220047536A (ko) 2022-04-18
JP2025041629A (ja) 2025-03-26
JP7875929B2 (ja) 2026-06-18
US11384146B2 (en) 2022-07-12

Similar Documents

Publication Publication Date Title
SG11202010934SA (en) Antibodies specific for gucy2c and uses thereof
EP3880239A4 (en) THERAPEUTIC SIRPalpha ANTIBODIES
EP3997127A4 (en) ANTIBODIES TARGETING DLL3 AND THEIR USES
IL289829A (en) Immunomodulatory antibodies and methods of use thereof
MX2023004314A (es) Anticuerpos ligando anti grupo de diferenciacion 40 (cd40) terapeuticos.
EP4001308A4 (en) ANTI-TIGIT ANTIBODIES AND USES THEREOF
EP3632932A4 (en) ANTI-CD40 ANTIBODIES, ANTIGEN BINDING FRAGMENT OF THIS ANTIGEN AND ASSOCIATED MEDICAL USE
EP3774888A4 (en) Anti-phf-tau antibodies and uses thereof
EP3976657A4 (en) ANTI-TRKA ANTIBODIES AND USES THEREOF
EP4041403A4 (en) ANTI-KIR3DL3 ANTIBODIES AND USES THEREOF
IL281397B (en) Human pd–l1 antibodies
EP3894439A4 (en) ANTI-PERIOSTIN ANTIBODIES AND USES THEREOF
EP3778916A4 (en) PROCEDURE FOR ANTIGEN TREATMENT
EP4025611A4 (en) ANTI-CXCR2 ANTIBODIES AND THEIR USES
CA3279395A1 (en) Galectin-7-specific monovalent antibodies and uses thereof
EP3983435A4 (en) ANTI-TALEN ANTIBODIES AND USES THEREOF
EP3727422A4 (en) SYSTEM AND METHOD FOR TREATING A DISEASE USING A HYPERSPECIFIC MODIFIED PROTEIN SYSTEM
HK40078061A (en) Antibodies against human trem-1 and uses thereof
HK40077849A (en) Antibodies directed against tenofovir and derivatives thereof
WO2015175599A3 (en) Immunotherapy with binding agents
HK40077274A (en) Anti-kir3dl3 antibodies and uses thereof
HK40071706A (en) Anti-il-27 antibodies and uses thereof
HK40075749A (en) Anti-ceacam antibodies and uses thereof
HK40065178A (en) Anti-trem1 antibodies and related methods
HK40078058A (zh) 抗trem-1抗体及其用途

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - DIVISIONAL

Effective date: 20260224

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD

Year of fee payment: 5

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20260228

A18 Application divided or continuation or continuation in part accepted

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A18-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DIVISIONAL REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260228

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P112 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY DOCUMENT OR RESPONSE DETERMINED COMPLIANT

Effective date: 20260228

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260228

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260228

P22 Classification modified

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED

Effective date: 20260327

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION PUBLISHED (OPEN TO PUBLIC INSPECTION)

Effective date: 20260513

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED

Effective date: 20260521

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20260521

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260521

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260603

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260618

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT

Effective date: 20260618

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260618

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260618

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260618